An interventional study of Blood, fluid, sells and urine samples in Sjogren's Syndrome, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by University Hospital, Brest · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Sjogren's Syndrome with a site in France — 18 open to participants now, 25 under way, 7 of them phase 3. Sjogren's Syndrome · France.
Among the 58 studies in Sjogren's Syndrome with a site in France, this one has the largest planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2020, is one of 12 with no phase, reaches primary completion later than 24 of the 24 other live ones, and was the 18th registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →18 of the 58 studies in Sjogren's Syndrome with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, United States, Australia and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in France, United States, Australia and 17 more countries
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
GlaxoSmithKline · Sites in France, Argentina, Brazil and 6 more countries
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 10 · Phase 4 1
First in 2008; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 169 across the 40 interventional studies, 110 across the 18 observational. Of the 27 that completed or were terminated, 9 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 58 have an industry lead sponsor. The 10 most frequent:
University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.
University Hospital, Brest has 6 studies filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Sjogren's Syndrome with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
| NCT06875102Centre Hospitalier Universitaire de Saint EtienneFatigue in Sjögren's Syndrome: 3 Therapeutic Strategies | 2027-04 |
| NCT06842316Centre Hospitalier Régional d'OrléansEffects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases | 2027-04-09 |
| NCT03003572Centre Hospitalier Universitaire de Saint EtienneAutoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity | 2027-06 |
| NCT05927688University Hospital, Strasbourg, FranceAssessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 58 studies in Sjogren's Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectif is to study the diagnosis performance of the different classification criteria in reference to the gold standard consisting of the diagnosis made by expert doctors after standardized assessment, of pSS (primary Sjogren syndrome)
The formation of this patient is single-center prospective intervention. It consists of collecting data from patients suspected of pSS from standardized biological clinical data and imaging examination and additional pathology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients diagnosed Sjögren
Other: Blood, fluid, sells and urine samples
patients diagnosed no Sjögren
Other: Blood, fluid, sells and urine samples
Blood, fluid, sells and urine samples will be collected.
Description specificity of different classification criteria FOR sJOGREN (EULAR/ACR 2019, european criteria)
Specificity of different classification criteria, the standard gold being the diagnosis obtained by consensus of expert doctors after standardized assessment.
Time frame: Inclusion
Number of patients with different manifestation including in the ESSDAI (Eular Sjögren Syndrome Disease Activity index), gold standard to measure
number of patients wit arthritis of more than 6 joints, parotidomegaly, intertitial lung disease
Time frame: 10 years
Number of patients with rheumatological manifestations
number of patients wit arthritis of more than 6 joints, parotidomegaly, intertitial lung disease
Time frame: 10 years
Number of patients with dermatological manifestations
number of patients wit arthritis of more than 6 joints, parotidomegaly, intertitial lung disease
Time frame: 10 years
Description diagnostic performance of new tests
after evaluation of all différents test performed added to the classical items of the ACR 2017: ie ultrasound parenchymal abnormalities, sub population of B cells....
Time frame: 10 years
Disease evolution criteria
modification of the ESSDAI at each visit
Time frame: 10 years
Started Feb 2020 (actual). Primary completion is estimated for Feb 2035, 180 months after the start.
Of 39 non-industry interventional studies with no phase under Sjogren's Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 180 months is above that.
Counting every sponsor, half of 44 studies reached it within 18 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.